Abstract:
A method for determining disease severity in a subject afflicted with a tauopathy-related neurodegenerative disease comprises detecting the level of a PINCH protein or isoform thereof in a test sample comprising brain tissue or cerebrospinal fluid. The PINCH protein level in the test sample indicates the relative severity of the tauopathy-related neurodegenerative disease afflicting the subject.
Abstract:
Apparatus, computer readable medium, and a method for interacting with a user on a computer for displaying grants, the method comprising displaying grants with an icon indicating a balance of the grant; and in response to a selection of one of the displayed grants comprising transactions by the user, displaying transactions of the selected grant in a row comprising a column for transactions that lower the balance, a column for transactions that raise the balance, and a column for the balance, and displaying an icon for the column for transactions that lowers the balance and an icon for the column for transactions that raises the balance. The method may comprise retrieving credits and debits and displaying in the column for transactions that lower the balance, credits and debits that lower the balance, and displaying in the column for transactions that raise the balance, credits and debits that raise the balance.
Abstract:
Compositions and kits useful for the treatment of myocardial infarction comprise (i) P-selectin-targeted carriers (e.g., P-selectin-targeted liposomes, quantum dots or biodegradable nanoparticles) comprising VEGF and (ii) MSCs.
Abstract:
Provided is a method for the treatment and/or prevention of an amyloid beta amyloidosis in a subject comprising the step of administering to the subject an effective amount of a 5-lipoxygenase-activating protein (FLAP) antagonist. In preferred embodiments, the FLAP antagonist is MK-591, or a pharmaceutically acceptable salt thereof. Also provided is a method for decreasing or preventing the deposition of beta amyloid in the brain of a subject comprising the step of administering to a subject an effective amount of a FLAP antagonist. In preferred embodiments, the FLAP antagonist is MK-591, or a pharmaceutically acceptable salt thereof.
Abstract:
The present invention relates to a method and an apparatus for producing a chocolate product. The method includes delivering liquid chocolate having a viscosity through a pipe along a delivery path to a production station for producing the chocolate product. The liquid chocolate includes solid particles suspended within the liquid chocolate. The method changes the viscosity of the liquid chocolate by applying an electric field to the liquid chocolate in a direction along the delivery path of a strength and duration determined to aggregate the suspended solid particles into streamlined shapes extending along the direction of the delivery path.
Abstract:
Styryl sulfone compounds of the invention selectively inhibit proliferation of tumor cells, and induce apoptosis of tumor cells, while sparing normal cells. The compounds, which are useful in the treatment of cancer and other proliferative disorders, have (a) the formula II: 1 wherein n is zero or one; R1 is selected from the group consisting of hydrogen, chlorine, fluorine and bromine; R2 is selected from the group consisting of hydrogen, chlorine, fluorine, bromine, methyl and methoxy; and R3 is selected from the group consisting of hydrogen, chlorine and fluorine; provided, R2 may not be methyl or methoxy when R1 and R3 are both hydrogen and n is zero or one; and R1, R2 and R3 may not all be hydrogen when n is one; (b) the formula III: 2 wherein R1 is selected from the group consisting of hydrogen, chlorine, fluorine and bromine; or (c) or the formula IV: 3 wherein R1 is selected from the group consisting of fluorine and bromine, and R2 is selected from the group consisting of 2-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl and 2-nitrophenyl.
Abstract:
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
Abstract:
The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.
Abstract:
Compositions and methods for the promotion of wound healing and tissue regeneration are described. The compositions and methods make use of water-soluble soy protein isolates (WSsoy), Fraction 5, Fraction 9, and/or bioactive peptide components of soy protein isolates. The invention also relates to the unexpected discovery that purified WSsoy forms gel-like matrices when suspended within certain concentration ranges in an aqueous environment. The compositions of the invention comprising WSsoy promote natural healing and have a low risk profile.
Abstract:
Compositions include CRISPR-associated endonuclease, and one or more isolated nucleic acid sequences encoding gRNAs, wherein each gRNA is complementary to a target sequence in a retroviral genome. At least one endonuclease targets a Mannosyl Oligosaccharide Glucosidase (MOGS).